GleamWall
中文EN

ORGO Organogenesis Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661181 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-24.3%
TTM net income YoY-13,567.9%
TTM EPS YoY-1,400.0%
Revenue 3-yr CAGR-7.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-24.5%
Net margin-38.4%
FCF margin-0.0%
EBITDA margin-20.0%

Returns

ROE-72.2%
ROA-30.8%
ROIC (approx.)-47.0%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets28.8%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.08x
Accruals ratio-33.2%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$45.46M$43.76M$37.23M$225.61M$150.86M$101.00M$86.69M$126.66M
Cost of revenue——————$23.72M$31.05M
Gross profit——————$62.97M$95.61M
R&D expense$7.96M$18.30M$15.16M$10.29M$13.22M$10.39M$10.64M$11.53M
SG&A expense$45.09M$53.97M$65.19M$100.17M$79.74M$73.81M$72.51M$73.86M
Operating income-$29.49M-$50.99M-$68.89M$63.29M$20.73M-$12.58M-$26.75M$10.22M
Interest expense—-$138,000-$380,000-$236,000-$415,000-$669,000-$961,000-$61,000
Pretax income-$29.62M-$50.88M-$68.47M$63.43M$21.16M-$11.83M-$25.78M$10.25M
Income tax$8,000$45.39M-$15.32M$19.73M-$407,000-$2.44M-$6.94M$2.58M
Net income-$29.63M-$96.27M-$53.16M$43.70M$21.57M-$9.39M-$18.84M$7.67M
EBITDA-$25.56M-$47.32M-$64.72M$67.36M$24.76M-$8.84M-$23.30M$13.83M
EPS (basic)-0.25-0.77-0.44—0.11-0.10-0.17—
EPS (diluted)-0.25-0.77-0.44—0.11-0.10-0.17—
Weighted avg. shares (diluted)128.99M128.67M127.80M—130.85M126.85M126.30M—
Balance sheet
Cash & equivalents$21.33M$46.10M$91.38M$93.68M$64.37M$73.73M$110.53M$136.15M
Receivables$92.69M$100.94M$116.91M$217.45M$168.78M$120.38M$103.32M$109.86M
Inventory$26.68M$29.28M$28.43M$29.63M$39.58M$33.04M$29.34M$26.22M
Current assets$158.13M$200.30M$268.50M$362.19M$299.75M$260.22M$268.16M$285.94M
PP&E, net$98.60M$101.53M$104.08M$103.71M$78.06M$75.61M$75.52M$89.13M
Goodwill$28.77M$28.77M$28.77M$28.77M$28.77M$28.77M$28.77M$28.77M
Intangibles$2.57M$3.00M$3.44M$9.14M$9.94M$10.79M$11.63M$12.47M
Total assets$368.90M$406.45M$519.99M$598.73M$509.83M$461.13M$467.39M$497.89M
Current liabilities$47.65M$56.96M$76.02M$100.12M$90.32M$65.84M$65.05M$77.48M
Total liabilities$106.16M$118.31M$138.65M$164.81M$123.85M$99.91M$99.33M$112.57M
Shareholders' equity$119.74M$148.27M$244.56M$300.13M$255.13M$233.24M$242.90M$262.90M
Shares outstanding129.79M128.67M128.67M126.95M126.91M126.85M126.85M125.73M
Cash flow statement
Operating cash flow-$18.59M-$31.65M$21.13M$39.42M$3.08M-$32.87M-$19.93M$10.94M
Capital expenditure$1.47M$1.10M$3.15M$4.65M$2.23M$3.64M$3.63M$3.36M
Free cash flow-$20.06M-$32.75M$17.98M$34.77M$844,000-$36.51M-$23.56M$7.58M
Investing cash flow$2.15M-$1.10M-$3.15M-$4.65M-$2.23M-$3.64M-$3.63M-$3.36M
Financing cash flow-$3.46M-$12.50M-$20.21M-$4.81M-$10.21M-$288,000-$2.06M$33.65M
Depreciation & amortization$3.93M$3.67M$4.17M$4.07M$4.03M$3.73M$3.44M$3.62M
Stock-based compensation$2.81M$3.05M$3.64M$4.32M$3.06M$2.54M$3.37M$2.89M

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.